Bloom Syndrome (Congenital Telangiectatic Erythema)

Back

Background

Bloom syndrome (congenital telangiectatic erythema) is a rare autosomal recessive disorder. It was first described in 1954 by David Bloom in a series of patients with telangiectatic erythema on the face and dwarfism.[1] Bloom syndrome has three cardinal features: sun sensitivity, telangiectatic erythema of the face, and stunted growth.

Owing to the genomic instability present in this disease, patients with Bloom syndrome show a much higher incidence of malignant neoplasms, which is the major cause of death in such patients. No patients have been reported to reach age 50 years.

Variable degrees of immunodeficiency are present in these patients, predisposing them to various infections; this acts as an additional factor for the high incidence of cancers in Bloom syndrome patients.

Pathophysiology

Bloom syndrome (congenital telangiectatic erythema) is caused by a mutation in both alleles of the gene designated BLM, traced to band 15q26.1.[2, 3, 4, 5]  (see the image below). BLM encodes 1417 amino acids that code for a protein in the nuclear matrix of growing cells, which is a member of the RecQ family of helicases. This protein plays a pivotal role in DNA recombination and repair. BML mutations thus result in defects in DNA repair and genomic instability in the somatic cells, predisposing the patients to cancer development.[6]



View Image

Crystal structure of the Bloom syndrome helicase BLM in complex with DNA (PDB ID: 4CGZ). Courtesy of Arthur Zalevsky (own work), via Wikimedia Commons....

The BLM mutations can be found in compound heterozygous forms, homozygous forms, or as single gene mutation forms.

There is a 10-fold increase in the sister chromatid exchanges,[7] in addition to the presence of chromatid gaps, breaks, and gross structural rearrangements.[7, 8]  Sister chromatid exchanges are considered a sensitive indicator for cell genome instability, as they are thought to be the outcome of DNA double-strand breaks resulting from homologous recombination repair.[9]

Over 60 mutations of the BLM gene have been found in Bloom syndrome. The most common mutation is the deletion of 6 nucleotides at position 2281 and their replacement with 7 others, which occurs most commonly in Ashkenazi Jews.[10]

In 1989, Nicotera et al suggested that the major biochemical defect in persons with Bloom syndrome is chronic overproduction of the superoxide radical anion. They thought that inefficient removal of peroxide might be responsible for the high rates of sister chromatid exchange and chromosomal damage in Bloom syndrome cells.[11]

MM1 and MM2 are proteins identified in Bloom syndrome and Fanconi anemia, creating a link between them. The gene encoding these proteins is FANCM. Both diseases show phenotypical similarity and both demonstrate bone marrow failure, skeletal growth deficiency, short stature, and predisposition to hematological malignancies, although they are genetically unrelated. Both diseases involve the BRAFT and FANCM complexes, which are important in DNA repair.[12, 13]

Bugreev et al suggest that a function of BLM is stimulation of RAD51 DNA pairing; results from their study show the importance of the RAD51 nucleoprotein filament conformation for stimulating DNA pairing by BLM.[14]

Photosensitivity in Bloom syndrome patients is a result of increased susceptibility to 313-nm light, approaching the ultraviolet (UV)–A range. The minimal erythema dose threshold for both UV-A and UV-B are reduced.[15] Cellular sensitivity in Bloom syndrome patients is in the form of phototoxicity and not photocarcinogenicity, as is seen in xeroderma pigmentosa.[16] Bloom syndrome patients exhibit a greater vulnerability of their DNA to UV radiation than DNA of healthy populations.

Bloom syndrome patients also demonstrate impairment in lymphocytic proliferation, deficient immunoglobulin synthesis, and lowered response to mitogen stimulation, resulting in impairment of both cellular and humoral immune responses.[17]

The overall result of the genomic instability in the proliferating cells is a high risk of malignancy, reduced fertility or infertility, B- and T-cell immunodeficiencies, and cutaneous manifestations, including photosensitivity, poikiloderma, and telangiectatic erythema.

Etiology

Bloom syndrome (congenital telangiectatic erythema) is genetic with an autosomal recessive pattern of inheritance. The gene locus is band 15q26.1.

Cytogenetic findings in a Bloom syndrome patient with acute myeloid leukemia of the French-American-British subtype M1 showed preferential occurrence of total or partial loss of chromosome 7.

Mutation of the DNA ligase I gene may account for the primary metabolic defect in Bloom syndrome, not due to a reduction in the number of protein molecules or to inhibitory substances, but rather to the ATP-binding and hydrolytic activity of the enzyme. DNA ligase I and DNA polymerase alpha are enzymes that function during DNA replication; DNA ligase II and DNA polymerase-beta function during DNA repair.[18]

Epidemiology

Frequency

United States

More than 170 case reports of Bloom syndrome (congenital telangiectatic erythema) have been made. The frequency of parental consanguinity is much greater than in the general population.

International

Bloom syndrome (congenital telangiectatic erythema) is more common in Ashkenazi Jews, with an estimated carrier frequency of 1:120 and a reported prevalence of approximately 1 in 48,000 persons, accounting for 25% of the patients in the Bloom syndrome patient registry.[19]

The Bloom Syndrome Registry (BSR) was established in 2009. The total number of patients is less than 300. Of the registered patients, 75.2% were non-Jews.[20] However, it has been reported in Japan and other countries, with increased risk in cases with parental consanguinity.

Race

Bloom syndrome (congenital telangiectatic erythema) is more common in eastern European Ashkenazi Jews.

Sex

The male-to-female ratio for Bloom syndrome (congenital telangiectatic erythema) is 1.3:1.

Age

Bloom syndrome (congenital telangiectatic erythema) occurs in the first few months of life.

Prognosis

Increased risk of premature death in the second or third decade occurs secondary to malignancies. Patients with Bloom syndrome (congenital telangiectatic erythema) are estimated to develop malignancy at a rate 150-300 times higher than the general population. Twenty percent of Bloom syndrome patients develop malignancy during their life time.[21]  Various types of leukemia develop at a mean age of 22 years. Patients who survive beyond age 22 years develop solid tumors at an average age of 35 years. Fortunately, these tumors are sensitive to chemotherapy and radiotherapy.

Early diagnosis of leukemia is, at present, not known to improve the chances of curative therapy. Frequent hematologic examinations in children are not advised for fear of untoward psychologic effects. Allogeneic marrow grafting has not been performed in Bloom syndrome patients. Men with Bloom syndrome are sterile; women have reduced fertility and a shortened reproductive span. Bloom syndrome patients who become pregnant are at high risk for premature delivery. Intelligence is usually normal, although mild deficiency has occurred in a few affected persons. Diabetes occurs in approximately 10% of individuals with Bloom syndrome.

Resistance to infections gradually improves with age, as do erythema and photosensitivity.

Patient Education

Bloom Syndrome Registry

Laboratory of Human Genetics

New York Blood Center

310 East 67th Street

New York, NY 10021

(212) 570-3075; Fax (212) 570-3195

Contact person: James L German III, MD

History

Growth delay is the most impressive clinical feature of Bloom syndrome (congenital telangiectatic erythema) and is usually the first manifestation that causes the parents to seek medical attention. Other associated physical features and immunodeficiency are not present or recognizable at birth. The growth deficiency has a prenatal onset, apparent from term birth measurements, and persists throughout life. More than half the children are significantly underdeveloped in physical stature until age 8 years.

Patients with Bloom syndrome demonstrate recurrent respiratory and gastrointestinal tract infections.

Physical Examination

Physical examination findings in Bloom syndrome (congenital telangiectatic erythema) vary and involve stunted growth, cutaneous manifestations, ocular manifestations, musculoskeletal manifestations, fertility concerns, immunologic manifestations, and a predisposition to malignancies, among others.

Stunted growth

Prenatal and postnatal growth deficiency is noted in Bloom syndrome patients. The length and weight are both affected, but with normal body proportion (primordial stunted growth). The average birth weight reported for children with Bloom syndrome was 1.868 g in females and 1.890 g in males.[22] The child typically has reduced subcutaneous fat, yielding a wasted appearance. Small stature results from intrauterine growth restriction and the constant postnatal growth restriction.[23]

The mean final adult stature reported in males was 148.5 cm and 141.5 cm in females, with a mean weight of 41.3 kg in males and 36.6 kg in females.[22] Despite this stunted growth, normal growth hormone production and secretion was noticed in these patients, as well as normal serum concentrations of insulinlike growth factor 1 and insulinlike growth factor binding protein 3.

Feeding problems

Feeding problems are typically significant in infants and children. There is lack of interest in eating. Some patients have gastroesophageal reflux, vomiting, and diarrhea. The low body mass index in these children was noted to improve after age 8 years, and some adults developed central obesity.[24]

Cutaneous manifestations

Skin findings in Bloom syndrome include telangiectatic erythema, which is usually not congenital, appearing on average at age 8 years. It appears as macules or plaques in a butterfly distribution on the face and other photodistributed areas (eg, ears, eyelids, forearms, dorsa of the hands). Blistering, hemorrhage and crusts may occur.

Patients with a dark skin phenotype demonstrate fewer cutaneous manifestations. Absence of photosensitivity, facial erythema, and telangiectasia was reported in Japanese and Latin American patients.[25]

The characteristic rash develops later in life, mainly on the face following a butterfly distribution on the cheeks and nose, mostly in the form of telangiectasia and erythema. It is exacerbated by sun exposure and may develop on other sun-exposed skin such as the dorsum of hands, forearms, and ears.[26]

Other cutaneous manifestations reported include cheilitis, fissuring, blistering, poikiloderma, eyebrow or eyelash hair loss, and alopecia areata.[27]

Extensive vesicular and bullous eruptions have been reported with sun exposure, and an absence of the characteristic photosensitivity has also been reported.[28, 29]

Café au lait macules with adjacent hypopigmented areas appear as twin spotting. They are fewer and smaller than in non–Bloom syndrome patients.[30]

There is increased risk for skin cancers. Basal cell carcinoma is the most common, followed by squamous cell carcinoma. Melanomas have not been reported in Bloom syndrome patients.[31] Most cancers had occurred in sun-exposed skin, but skin of hip and base of the penis have been reported.[32] Multiplicity of skin cancer in individual patients is uncommon. However, multiple basal cell carcinomas on the face and neck in a Bloom syndrome patient have been reported.[33]

Facial features

Bloom syndrome patients show variable facial features, commonly a long and narrow face, retrognathia or micrognathia, and an underdeveloped malar area. The head circumference of most patients with Bloom syndrome is below the third percentile. The nose and/or ears of Bloom syndrome patients are often prominent, owing to the decreased amount of subcutaneous fat.[22]

Ocular manifestations

Scleral telangiectasias, bulbar conjunctival telangiectasia, conjunctivitis, sectoral iris pigment alteration, lens opacities, leukemic retinopathy, retinoblastoma, lateral strabismus, ectropion, and bilateral optic nerve hypoplasia are reported.[34, 35]

Musculoskeletal abnormalities

Affected individuals have long limbs, disproportionally large hands and feet, and progressive contracture of hands and feet. Upper extremities are long in proportion to body length.

Quick, birdlike movements are characteristic.

Clinodactyly and syndactyly may be seen.[36]

Fertility

Male patients are infertile (primary hypogonadism), and female patients are subfertile (premature menopause).

Immunologic abnormalities

Patients with Bloom syndrome are predisposed to respiratory and gastrointestinal infections as a result of a deficiency of immunoglobulin A.[17] Bacterial infections are more frequent than viral infections. Chronic lung disease is the second leading cause of death in Bloom syndrome patients.[37]

It should be noted that most Bloom syndrome patients do not have meningitis, bacterial sepsis, pneumonia, recurrent abscesses, or opportunistic infections, as are seen in primary immunodeficiency patients.[38]

Predisposition to malignancy

There is marked predisposition to early development of cancer. About 25% of patients develop malignancy, at a mean age of 20.7 years. Neoplasms of all types and sites may develop. The most common cancers reported in Bloom syndrome include lymphomas, leukemia, oral/esophageal squamous cell carcinoma, and adenocarcinoma of the sigmoid colon.[39]

More than one cancer occurring in a patient has been reported.[40] BLM mutation was found to increase the susceptibility to breast cancer, and a higher probability of colorectal carcinoma was found in heterozygous carriers of the BLM mutation.[41, 42] Bloom syndrome registry data suggest that 46% of registered patients develop cancers, with epithelial tumors being most frequent (52.5%), followed by lymphoid neoplasms (24%).[20] It was reported that 12% of Bloom syndrome patients develop colorectal cancer, mainly in their second decade of life.[40]

Other general associations

Patients have a high-pitched voice. Congenital heart disease and annular pancreas have been reported. Type 2 diabetes mellitus develops in about 15% of patients, and the risk increases with age.[37] Severe pulmonary involvement with parenchymal destruction, respiratory failure, emphysema, and bronchiectasia has been reported in Bloom syndrome. It has been suggested that recurrent lower respiratory tract infections since childhood could play a role in these changes.[43, 44] Other uncommon features include eyebrow hair loss, alopecia areata, reticular pigmentation on the forehead and trunk, flat nose, wide fingernails, and short sharpened distal phalanges.[45]

Complications

Men with Bloom syndrome (congenital telangiectatic erythema) are sterile; women have reduced fertility and a shortened reproductive span.

Recurrent respiratory and gastrointestinal tract infections and the development of chronic lung disease are additional complications, as is the early development of different types of cancers at any site. Type 2 diabetes is found in 15.8% of patients.[20]

Approach Considerations

Bloom syndrome should be suspected if any of the clinical or cytogenetic criteria described below are found.[47]

Clinical findings are as follows:

Cytogenetic findings are as follows:

Laboratory Studies

The diagnosis of Bloom syndrome (congenital telangiectatic erythema) can be confirmed or excluded by a laboratory test known as a chromosome study; blood and skin cells show a characteristic pattern of chromosome breakage and rearrangement. Testing for chromosome instability, including the presence of quadriradicals and increased sister chromatid exchanges, is performed at the US National Institutes of Health and US Armed Forces Institute of Pathology laboratories.

Prenatal diagnosis

Prenatal diagnosis of Bloom syndrome is possible with amniocentesis for amniotic fluid cell culture to assess for a high number of sister chromatid exchanges; DNA analysis will be available in the near future.

Genetic screening and counseling

Genetic screening is recommended for populations at high risk for being a carrier of the disease, such as Ashkenazi Jews. Targeted mutation analysis and polymerase chain reaction (PCR) to examine the DNA for the BLM 6-deletion/7-insertion mutation should be performed.

Genetic counseling could be offered to parents of patients with Bloom syndrome. Being an autosomal recessive disease in its mode of transmission, the risk of having the disease in siblings of heterozygous carriers is estimated to be 25%.[48]

Screening for complications

Immunoglobulin levels should be checked; decreased immunoglobulin A and immunoglobulin M, with or without immunoglobulin G changes, are expected.

There is no consensus regarding cancer surveillance in Bloom syndrome patients. The most important recommendation is to observe Bloom syndrome patients for any signs and symptoms that warrant further investigations (eg, complete blood cell count with any constitutional symptoms). Unintentional weight loss should be investigated thoroughly. Screening colonoscopy could be considered from age 16 years and carried out regularly, but there is no consensus for the appropriate interval.[38]

Periodic evaluation for leukemia and early screening for breast, cervical, and colorectal cancers are recommended. MRI and ultrasonography are recommended rather than other radiologic diagnostic modalities, in order to minimize the exposure to radiation in such vulnerable patients.

Other Tests

See the Workup section in the Medscape article Short Stature for detailed information on the workup for short stature.

Evaluation of children with photosensitivity

Phototesting and photopatch testing could be performed. Screening for antinuclear antibodies (ANA) and performing a porphyrin profile to exclude the possibility of lupus erythematosus or erythropoietic porphyria may be warranted.

Skin biopsy

Histopathologic findings from skin biopsies taken from the erythematous lesions show a lupuslike picture: follicular plugging, interface dermatitis, monocellular infiltrate, and perivascular infiltrate. However, the presence of changes in the basement membrane, periadnexal lymphocytic infiltration, and dermal mucin are very rare.[46] Bandlike dense lymphoid infiltrates with epidermotropism, resembling mycosis fungoides, have been reported.

Medical Care

Bloom syndrome (congenital telangiectatic erythema) has no specific treatment, but general management recommendations have been published by Cunniff et al.[49]

Skin

Avoid excessive sun exposure. Cover exposed skin with clothing and use a broad-brimmed hat and UV-blocking sunglasses. Frequent use of sun screens is recommended. Efforts to minimize exposure to other known environmental mutagens are also advisable.[50] Identification of café-au-lait macules by dermatologists would help to identify the risk of neoplasms in these patients.[51]

Psychosocial

Family and teachers are encouraged to relate to Bloom syndrome patients appropriately for their chronologic age rather than the younger age suggested by their unusually small size.

Growth

Growth hormone administration has been reported in the literature to improve linear growth. However, if there is lack of response regarding the velocity of growth, growth hormone should be discontinued owing to increased risk of tumor development. Serum IgE-1 and IgFBp-3levels should be monitored closely during treatment administration.

Nutrition

Gastroenterologist or feeding specialist consultation, institution of high-calorie diets with caution for high-fat or high-cholesterol diet, institution of reflux precautions, and use of antireflux medications are recommended.

Other

Infants, toddlers, and preschool-age children should be closely monitored for cognitive development and school performance.

Diabetes mellitus, thyroid abnormalities, and dyslipidemia should be managed according to standard protocols.

Immunoglobulin replacement can be instituted in cases of severe hypogammaglobulinemia.

Infections and cancerInfections should be managed thoroughly.

Medical treatment of cancers in patients with Bloom syndrome has many challenges; chemotherapy-induced toxicity and the immunodeficiency inherent to the disease may require reductions in the dose and number of treatment cycles of chemotherapy,[52] as it was found that standard chemotherapy has resulted in significant toxicity and some were life threatening. Alkylating agents may increase the risk of secondary malignancy; therefore, they should be avoided. Bloom syndrome and mature B-cell lymphoma has been successfully treated with rituximab.[53]

Surgical Care

Surgical oncology care can be instituted as needed for the diagnosis and treatment of malignancies.

Consultations

The following consultations may be warranted in Bloom syndrome (congenital telangiectatic erythema):

Activity

Men with Bloom syndrome (congenital telangiectatic erythema) are sterile; women have reduced fertility and a shortened reproductive span. A 19-year-old woman with Bloom syndrome was reported with a successful pregnancy.[54] Preterm labor occurred at 32 weeks' gestation, and the infant was ultimately delivered at 35 weeks' gestation. The infant was at less than the tenth percentile for length and weight for gestational age, but was otherwise healthy. Because preterm labor had occurred in this and a previously reported pregnancy in women with Bloom syndrome, increased surveillance for preterm labor in pregnancies of women with Bloom syndrome is suggested.

Strict photoprotection should be practiced by these patients.

What is Bloom syndrome (congenital telangiectatic erythema)?What is the pathophysiology of Bloom syndrome (congenital telangiectatic erythema)?What causes Bloom syndrome (congenital telangiectatic erythema)?What is the prevalence of Bloom syndrome (congenital telangiectatic erythema) in the US?What is the global prevalence of Bloom syndrome (congenital telangiectatic erythema)?What are the racial predilections of Bloom syndrome (congenital telangiectatic erythema)?What are the sexual predilections of Bloom syndrome (congenital telangiectatic erythema)?At what age does Bloom syndrome (congenital telangiectatic erythema) typically present?What is the prognosis of Bloom syndrome (congenital telangiectatic erythema)?Which clinical history findings are characteristic of Bloom syndrome (congenital telangiectatic erythema)?Which physical findings are characteristic of Bloom syndrome (congenital telangiectatic erythema)?How does Bloom syndrome (congenital telangiectatic erythema) affect prenatal and postnatal growth?Which GI findings are characteristic of Bloom syndrome (congenital telangiectatic erythema)?Which cutaneous findings are characteristic of Bloom syndrome (congenital telangiectatic erythema)?Which facial features are characteristic of Bloom syndrome (congenital telangiectatic erythema)?Which ocular findings are characteristic of Bloom syndrome (congenital telangiectatic erythema)?Which musculoskeletal findings are characteristic of Bloom syndrome (congenital telangiectatic erythema)?How does Bloom syndrome (congenital telangiectatic erythema) affect fertility?Which immunologic findings are characteristic of Bloom syndrome (congenital telangiectatic erythema)?What is the risk of malignancy in patients with Bloom syndrome (congenital telangiectatic erythema)?Which co-morbidities of Bloom syndrome (congenital telangiectatic erythema)?What are the possible complications of Bloom syndrome (congenital telangiectatic erythema)?How is Cockayne syndrome differentiated from Bloom syndrome (congenital telangiectatic erythema)?How is Rothmund-Thomson syndrome differentiated from Bloom syndrome (congenital telangiectatic erythema)?How is lupus erythematosus differentiated from Bloom syndrome (congenital telangiectatic erythema)?How is erythropoietic protoporphyria differentiated from Bloom syndrome (congenital telangiectatic erythema)?What are the differential diagnoses for Bloom Syndrome (Congenital Telangiectatic Erythema)?How is Bloom syndrome diagnosed?What is the role of lab tests in the workup of Bloom syndrome (congenital telangiectatic erythema)?How is Bloom syndrome (congenital telangiectatic erythema) diagnosed prenatally?When is genetic screening and counseling indicated for Bloom syndrome (congenital telangiectatic erythema)?How are patients with Bloom syndrome (congenital telangiectatic erythema) screened for complications?How is photosensitivity assessed in Bloom syndrome (congenital telangiectatic erythema)?Which histologic findings are characteristic of Bloom syndrome (congenital telangiectatic erythema)?How is Bloom syndrome (congenital telangiectatic erythema) treated?What are the dermatologic treatments for Bloom syndrome (congenital telangiectatic erythema)?What should parents and teachers be educated about Bloom syndrome (congenital telangiectatic erythema)?What is the role of growth hormones in the treatment of Bloom syndrome (congenital telangiectatic erythema)?Which dietary modifications are used in the treatment of Bloom syndrome (congenital telangiectatic erythema)?What is included in the long-term monitoring of Bloom syndrome (congenital telangiectatic erythema)?What is the role of surgery in the treatment of Bloom syndrome (congenital telangiectatic erythema)?Which specialist consultations are beneficial to patients with Bloom syndrome (congenital telangiectatic erythema)?How does Bloom syndrome (congenital telangiectatic erythema) affect pregnancy outcomes?

Author

Amira M Elbendary, MBBCh, MSc, Visiting Dermatopathology Fellow, Ackerman Academy of Dermatopathology; Assistant Lecturer, Department of Dermatology, Kasr Alainy University Hospitals, Cairo University, Egypt

Disclosure: Nothing to disclose.

Coauthor(s)

Dirk M Elston, MD, Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Disclosure: Nothing to disclose.

Specialty Editors

Michael J Wells, MD, FAAD, Dermatologic/Mohs Surgeon, The Surgery Center at Plano Dermatology

Disclosure: Nothing to disclose.

Van Perry, MD, Assistant Professor, Department of Medicine, Division of Dermatology, University of Texas School of Medicine at San Antonio

Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD, Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Disclosure: Nothing to disclose.

Additional Contributors

Eleanor E Sahn, MD, Director, Division of Pediatric Dermatology, Associate Professor, Departments of Dermatology and Pediatrics, Medical University of South Carolina

Disclosure: Nothing to disclose.

Acknowledgements

Amir A Bajoghli, MD Clinical Assistant Professor of Dermatology, George Washington University School of Medicine and Georgetown University; Chief, Dermatology and Mohs Surgery Section, Inova Fairfax Hospital; Dermatologist, Skin and Laser Surgery Center, PC

Amir A Bajoghli, MD is a member of the following medical societies: American Academy of Dermatology, American Medical Association, and Massachusetts Medical Society

Disclosure: Nothing to disclose.

References

  1. Bloom D. Congenital telangiectatic erythema resembling lupus erythematosus in dwarfs; probably a syndrome entity. AMA Am J Dis Child. 1954 Dec. 88(6):754-8. [View Abstract]
  2. Straughen J, Ciocci S, Ye TZ, et al. Physical mapping of the bloom syndrome region by the identification of YAC and P1 clones from human chromosome 15 band q26.1. Genomics. 1996 Jul 1. 35(1):118-28. [View Abstract]
  3. Park CJ, Ko J, Ryu KS, Choi BS. Solution structure of the RecQ C-terminal domain of human Bloom syndrome protein. J Biomol NMR. 2014 Feb. 58(2):141-7. [View Abstract]
  4. Kim SY, Hakoshima T, Kitano K. Structure of the RecQ C-terminal domain of human Bloom syndrome protein. Sci Rep. 2013 Nov 21. 3:3294. [View Abstract]
  5. Salah GB, Salem IH, Masmoudi A, Rhouma BB, Turki H, Fakhfakh F, et al. Chromosomal instability associated with a novel BLM frameshift mutation (c.1980-1982delAA) in two unrelated Tunisian families with Bloom syndrome. J Eur Acad Dermatol Venereol. 2014 Oct. 28(10):1318-23. [View Abstract]
  6. Payne M, Hickson ID. Genomic instability and cancer: lessons from analysis of Bloom's syndrome. Biochem Soc Trans. 2009 Jun. 37:553-9. [View Abstract]
  7. Seki M, Nakagawa T, Seki T, et al. Bloom helicase and DNA topoisomerase IIIalpha are involved in the dissolution of sister chromatids. Mol Cell Biol. 2006 Aug. 26(16):6299-307. [View Abstract]
  8. LaRocque JR, Stark JM, Oh J, Bojilova E, Yusa K, Horie K, et al. Interhomolog recombination and loss of heterozygosity in wild-type and Bloom syndrome helicase (BLM)-deficient mammalian cells. Proc Natl Acad Sci U S A. 2011 Jul 19. 108(29):11971-6. [View Abstract]
  9. Aguilera A, Gómez-González B. Genome instability: a mechanistic view of its causes and consequences. Nat Rev Genet. 2008 Mar. 9 (3):204-17. [View Abstract]
  10. Risch N, Tang H, Katzenstein H, Ekstein J. Geographic distribution of disease mutations in the Ashkenazi Jewish population supports genetic drift over selection. Am J Hum Genet. 2003 Apr. 72(4):812-22. [View Abstract]
  11. Nicotera TM, Notaro J, Notaro S, Schumer J, Sandberg AA. Elevated superoxide dismutase in Bloom's syndrome: a genetic condition of oxidative stress. Cancer Res. 1989 Oct 1. 49(19):5239-43. [View Abstract]
  12. Deans AJ, West SC. FANCM connects the genome instability disorders Bloom's Syndrome and Fanconi Anemia. Mol Cell. 2009 Dec 25. 36(6):943-53. [View Abstract]
  13. Guo R, Xu D, Wang W. Identification and analysis of new proteins involved in the DNA damage response network of Fanconi anemia and Bloom syndrome. Methods. 2009 May. 48(1):72-9. [View Abstract]
  14. Bugreev DV, Mazina OM, Mazin AV. Bloom syndrome helicase stimulates RAD51 DNA strand exchange activity through a novel mechanism. J Biol Chem. 2009 Sep 25. 284(39):26349-59. [View Abstract]
  15. Zbinden I, Cerutti P. Near-ultraviolet sensitivity of skin fibroblasts of patients with Bloom's syndrome. Biochem Biophys Res Commun. 1981 Feb 12. 98(3):579-87. [View Abstract]
  16. Lehmann AR, Kirk-Bell S, Arlett CF, Paterson MC, Lohman PH, de Weerd-Kastelein EA, et al. Xeroderma pigmentosum cells with normal levels of excision repair have a defect in DNA synthesis after UV-irradiation. Proc Natl Acad Sci U S A. 1975 Jan. 72(1):219-23. [View Abstract]
  17. Hütteroth TH, Litwin SD, German J. Abnormal immune responses of Bloom's syndrome lymphocytes in vitro. J Clin Invest. 1975 Jul. 56(1):1-7. [View Abstract]
  18. Garcia AM, Salomon RN, Witsell A, Liepkalns J, Calder RB, Lee M, et al. Loss of the Bloom Syndrome helicase increases DNA ligase 4-independent genome rearrangements and tumorigenesis in aging Drosophila. Genome Biol. 2011 Dec 19. 12(12):R121. [View Abstract]
  19. Li L, Eng C, Desnick RJ, German J, Ellis NA. Carrier frequency of the Bloom syndrome blmAsh mutation in the Ashkenazi Jewish population. Mol Genet Metab. 1998 Aug. 64(4):286-90. [View Abstract]
  20. Weill Cornell Medical College, Bloom’s Syndrome Registry. A Concise Clinical Description of Bloom’s Syndrome. Available at http://weill.cornell.edu/bsr/clinical_description/. 2009; Accessed: February 16, 2017.
  21. Kaneko H, Inoue R, Fukao T, Kasahara K, Tashita H, Teramoto T, et al. Two Japanese siblings with Bloom syndrome gene mutation and B-cell lymphoma. Leuk Lymphoma. 1997 Nov. 27(5-6):539-42. [View Abstract]
  22. Keller C, Keller KR, Shew SB, Plon SE. Growth deficiency and malnutrition in Bloom syndrome. J Pediatr. 1999 Apr. 134 (4):472-9. [View Abstract]
  23. Passarge E. Bloom’s syndrome. German J, ed. Chromosome Mutation and Neoplasia. New York, NY: Alan R. Liss; 1983. 11–21.
  24. Diaz A, Vogiatzi MG, Sanz MM, German J. Evaluation of short stature, carbohydrate metabolism and other endocrinopathies in Bloom's syndrome. Horm Res. 2006. 66 (3):111-7. [View Abstract]
  25. Chavez-Alvarez S, Villarreal-Martinez A, Velasco-Campos MDR, Moreno-Vega I, Martinez-de-Villarreal LE, Herz-Ruelas M, et al. Bloom syndrome sans characteristic facial features in a Mestizo patient- a diagnostic challenge. Indian J Dermatol Venereol Leprol. 2019 Jan-Feb. 85 (1):130. [View Abstract]
  26. Arora H, Chacon AH, Choudhary S, McLeod MP, Meshkov L, Nouri K, et al. Bloom syndrome. Int J Dermatol. 2014 Jul. 53 (7):798-802. [View Abstract]
  27. Jian-Bing W, Cheng-Rang L, Yi-Ping M, Nan S, Hui L, Lin L. A case of Bloom syndrome with uncommon clinical manifestations confirmed on genetic testing. Cutis. 2016 Feb. 97 (2):E10-3. [View Abstract]
  28. Vojtková J, Čiljaková M, Jeseňák M, Mišovicová N, Bánovčin P. Bloom syndrome without typical sun-sensitive skin lesions in three Slovak siblings. Int J Dermatol. 2015 Sep 4. [View Abstract]
  29. Vojtková J, Čiljaková M, Jeseňák M, Mišovicová N, Bánovčin P. Bloom syndrome without typical sun-sensitive skin lesions in three Slovak siblings. Int J Dermatol. 2016 Jun. 55 (6):687-690. [View Abstract]
  30. Masmoudi A, Marrakchi S, Kamoun H, Chaaben H, Ben Salah G, Ben Salah R, et al. Clinical and laboratory findings in 8 patients with Bloom's syndrome. J Dermatol Case Rep. 2012 Mar 27. 6 (1):29-33. [View Abstract]
  31. Sanz MM, German J, Cunniff C. Pagon RA, Adam MP, Ardinger HH, et al. GeneReviews® [Internet]. Seattle, Wash: University of Washington; April 7, 2016.
  32. Ozawa T, Kondo N, Motoyoshi F, Kasahara K, Orii T. DNA mutation induced in the sequence upstream of the secreted MYU C-terminal coding sequence by ultraviolet irradiation in the cell line of Bloom's syndrome. Eur J Immunogenet. 1995 Apr. 22 (2):163-9. [View Abstract]
  33. Draznin M, Robles DT, Nguyen V, Berg D. An unusual case of Bloom syndrome presenting with basal cell carcinoma. Dermatol Surg. 2009 Jan. 35 (1):131-4. [View Abstract]
  34. Bhisitkul RB, Rizen M. Bloom syndrome: multiple retinopathies in a chromosome breakage disorder. Br J Ophthalmol. 2004 Mar. 88(3):354-7. [View Abstract]
  35. Aljarad S, Alhamid A, Rahmeh AR, Alibraheem A, Wafa A, Alachkar W, et al. Bloom syndrome with myelodysplastic syndrome that was converted into acute myeloid leukaemia, with new ophthalmologic manifestations: the first report from Syria. Oxf Med Case Reports. 2018 Dec. 2018 (12):omy096. [View Abstract]
  36. Sultan SJ, Sultan ST. Bloom syndrome in two siblings. Pediatr Dermatol. 2010 Mar-Apr. 27(2):174-7. [View Abstract]
  37. German J. The immunodeficiency of Bloom syndrome. Ochs HD, Smith CIE, Puck JM, eds. Primary Immunodeficiency Diseases: A Molecular and Genetic Approach. New York, NY: Oxford University Press; 1999. 335.
  38. Cunniff C, Bassetti JA, Ellis NA. Bloom's Syndrome: Clinical Spectrum, Molecular Pathogenesis, and Cancer Predisposition. Mol Syndromol. 2017 Jan. 8 (1):4-23. [View Abstract]
  39. Amor-Guéret M. Bloom syndrome, genomic instability and cancer: the SOS-like hypothesis. Cancer Lett. 2006 May 8. 236(1):1-12. [View Abstract]
  40. German J. Bloom's syndrome. XX. The first 100 cancers. Cancer Genet Cytogenet. 1997 Jan. 93 (1):100-6. [View Abstract]
  41. Gruber SB, Ellis NA, Scott KK, Almog R, Kolachana P, Bonner JD, et al. BLM heterozygosity and the risk of colorectal cancer. Science. 2002 Sep 20. 297 (5589):2013. [View Abstract]
  42. Prokofyeva D, Bogdanova N, Dubrowinskaja N, Bermisheva M, Takhirova Z, Antonenkova N, et al. Nonsense mutation p.Q548X in BLM, the gene mutated in Bloom's syndrome, is associated with breast cancer in Slavic populations. Breast Cancer Res Treat. 2013 Jan. 137 (2):533-9. [View Abstract]
  43. Relhan V, Sinha S, Bhatnagar T, Garg VK, Kochhar A. Bloom syndrome with extensive pulmonary involvement in a child. Indian J Dermatol. 2015 Mar-Apr. 60 (2):217. [View Abstract]
  44. Nair G, Lobo I, Jayalaksmi TK, Uppe A, Jindal S, Chandra A, et al. Bloom syndrome with lung involvement. Lung India. 2009 Jul. 26 (3):92-4. [View Abstract]
  45. Jian-Bing W, Cheng-Rang L, Yi-Ping M, Nan S, Hui L, Lin L. A case of Bloom syndrome with uncommon clinical manifestations confirmed on genetic testing. Cutis. 2016 Feb. 97 (2):E10-3. [View Abstract]
  46. McGowan J, Maize J, Cook J. Lupus-Like Histopathology in Bloom Syndrome: Reexamining the Clinical and Histologic Implications of Photosensitivity. Am J Dermatopathol. 2009 Oct 8. [View Abstract]
  47. Sanz MM, German J, Cunniff C. Bloom's Syndrome. Pagon RA, Adam MP, Ardinger HH, et al, eds. GeneReviews® [Internet]. University of Washington, Seattle; 2006 Mar 22 [Updated 2019].
  48. Arora H, Chacon AH, Choudhary S, McLeod MP, Meshkov L, Nouri K, et al. Bloom syndrome. Int J Dermatol. 2014 Jul. 53(7):798-802. [View Abstract]
  49. Cunniff C, Djavid AR, Carrubba S, Cohen B, Ellis NA, Levy CF, et al. Health supervision for people with Bloom syndrome. Am J Med Genet A. 2018 Sep. 176 (9):1872-1881. [View Abstract]
  50. Thomas ER, Shanley S, Walker L, Eeles R. Surveillance and treatment of malignancy in Bloom syndrome. Clin Oncol (R Coll Radiol). 2008 Jun. 20(5):375-9. [View Abstract]
  51. Karalis A, Tischkowitz M, Millington GW. Dermatological manifestations of inherited cancer syndromes in children. Br J Dermatol. 2011 Feb. 164 (2):245-56. [View Abstract]
  52. Oto S, Miyamoto S, Kudoh F, Horie H, Kinugawa N, Okimoto Y. Treatment for B-cell-type lymphoma in a girl associated with Bloom's syndrome. Clin Genet. 1992 Jan. 41 (1):46-50. [View Abstract]
  53. Jastaniah W. Successful treatment of mature B-cell lymphoma with rituximab-based chemotherapy in a patient with Bloom syndrome. Pediatr Blood Cancer. 2016 Dec 14. [View Abstract]
  54. Chisholm CA, Bray MJ, Karns LB. Successful pregnancy in a woman with Bloom syndrome. Am J Med Genet. 2001 Aug 1. 102(2):136-8. [View Abstract]

Crystal structure of the Bloom syndrome helicase BLM in complex with DNA (PDB ID: 4CGZ). Courtesy of Arthur Zalevsky (own work), via Wikimedia Commons.

Crystal structure of the Bloom syndrome helicase BLM in complex with DNA (PDB ID: 4CGZ). Courtesy of Arthur Zalevsky (own work), via Wikimedia Commons.